Tonix Posts $17.2M Q3 Revenue as TONMYA Launch Gains Traction

By Grace Kim

Tonix Pharmaceuticals (NASDAQ:TNXP) booked approximately $17.2 million in total net product revenue in the third quarter, up from $3.3 million a year earlier, with its newly launched fibromyalgia drug TONMYA contributing roughly $15 million of that — a 37% increase from the second quarter.

The prior-year figure consisted entirely of sales from Tonix's migraine products, Zembrace SymTouch and TOSYMRA. TONMYA launched in November 2025, and the third quarter marked its first full quarter of commercial scale. CEO Seth Lederman credited previously signed payer agreements and a sales force expansion completed Sept. 1 for the jump.

The number that matters to CFOs here: management says cash on hand plus post-quarter equity proceeds funds operations into early Q3 2027.

What's driving TONMYA's top line?

TONMYA prescriptions totaled 16,375 in the third quarter, up 28% from the second quarter, according to Chief Commercial Officer Thomas Englese. New prescriptions rose 17%. Refills climbed 56%.

Englese attributed revenue growth to several factors:

• Payer agreements signed in May and June
• More favorable gross-to-net adjustments (the gap between a drug's list price and what payers actually pay) than expected
• Execution of the launch strategy
• A shift toward 60-count bottles from 30-count bottles, which lifted average prices

He flagged that gross-to-net fluctuations are expected early in a launch.

Coverage now reaches approximately 53% of covered lives in the U.S. Tonix signed two managed Medicare agreements during the quarter and is pursuing more payer contracts. Bridge prescriptions through the digital specialty pharmacy BlinkRx declined as a share of total prescriptions as coverage expanded, though Englese did not provide the specific percentage for Q3.

Following the expansion to 150 sales representatives, Tonix is now targeting roughly 70% of an estimated 25,000 healthcare providers who diagnose and treat fibromyalgia, up from about 40% before the expansion. Englese reported increases in both new and total prescribers after Sept. 1 but did not provide counts.

In short: more covered lives plus a bigger sales force equals a wider prescriber base.

How serious is the generic challenge?

On Oct. 1, Tonix received notice that Dr. Reddy's Laboratories had filed an abbreviated new drug application with a Paragraph IV patent certification for TONMYA — a legal mechanism generic makers use to challenge branded patents before expiry.

Lederman said Tonix "would vigorously defend its intellectual property" and that its core patents, as currently granted, provide protection into 2034. He declined to give detailed litigation updates.

Where is the cash going?

Third-quarter R&D expenses rose to approximately $25.8 million from $9.3 million a year earlier, driven by higher manufacturing, clinical, non-clinical and employee-related costs, CFO Bradley Saenger said. Selling, general and administrative expenses increased to approximately $45.6 million from $25.7 million, largely on sales and marketing, employee and professional expenses tied to the TONMYA launch.

Tonix ended September with approximately $162.8 million in cash and cash equivalents, down from $207.6 million at the end of 2025. Saenger said that cash, together with net proceeds from an equity offering completed after quarter-end, should fund operating and capital expenditure requirements into early in the third quarter of 2027.

The burn math: spending nearly doubled year-over-year, but the runway is secured for roughly two more years.

What's next in the pipeline?

Tonix is enrolling participants in HORIZON, a potentially pivotal Phase II study of TNX-102 SL as a first-line monotherapy for adults with major depressive disorder. A successful program could support an expansion of TONMYA's label, Lederman said, though it's too early to guide on enrollment completion or top-line results.

The company also plans TRAIL, an adaptive Phase II field study of its Lyme disease prevention candidate TNX-4800, starting in Q1 2027. The study would enroll approximately 3,300 adults over two Lyme seasons, beginning with a roughly 500-person cohort focused primarily on safety as well as efficacy. Lederman said Tonix received favorable FDA meeting minutes on the study design and has submitted a protocol for review; he doesn't expect significant changes but couldn't give a timeline for finalization. After a safety review, the balance of the efficacy cohort would be enrolled during the 2028 Lyme season.

An investigator-initiated Phase II study of TNX-1500, an antibody to prevent kidney transplant rejection, is expected to begin at Massachusetts General Hospital in Q1 2027 and enroll five patients, with an 18-month primary endpoint and interim assessments earlier.

On TNX-1300, being developed for cocaine intoxication, Lederman said Tonix has met with the FDA and is awaiting a response on a proposed approval path based on laboratory studies. Clinical development remains at an impasse until the parties agree on a path forward.

The bottom line: a fast-ramping launch, a funded runway to mid-2027, and one generic fight Tonix says it's ready for.